{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:35:03Z","timestamp":1760402103266,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM\/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive\/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs.<\/jats:p>","DOI":"10.3390\/jcm10071503","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:48:29Z","timestamp":1617623309000},"page":"1503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Seroprevalence of SARS-CoV-2\u2013Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-4758","authenticated-orcid":false,"given":"Luca","family":"Cantini","sequence":"first","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Bastianelli","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Lupi","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-2104","authenticated-orcid":false,"given":"Giada","family":"Pinterpe","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Belletti","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Stoico","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vitarelli","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moretti","sequence":"additional","affiliation":[{"name":"SOD Medicina di Laboratorio, A.O.U. Ospedali Riuniti, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Onori","sequence":"additional","affiliation":[{"name":"SOD Medicina di Laboratorio, A.O.U. Ospedali Riuniti, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Giampieri","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-5795","authenticated-orcid":false,"given":"Marco Bruno Luigi","family":"Rocchi","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-2960","authenticated-orcid":false,"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[{"name":"Rossana Berardi, Clinical Oncology, Universit\u00e0 Politecnica delle Marche, A.O.U. Ospedali Riuniti, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_3","first-page":"1","article-title":"SARS-CoV-2 and cancer: Are they really partners in crime?","volume":"89","author":"Huizing","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","article-title":"Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study","volume":"21","author":"Tian","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-020-05667-6","article-title":"Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City","volume":"182","author":"Kalinsky","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): First results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41571-020-0394-y","article-title":"COVID-19 and cancer: Do we really know what we think we know?","volume":"17","author":"Robinson","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rode, O.\u0110., Kurolt, I.C., Puljiz, I., \u010civljak, R., Balent, N.C., La\u0161kaj, R., Tiljak, M.K., Mikuli\u0107, R., and Markoti\u0107, A. (2020). Antibody response and the clinical presentation of patients with COVID-19 in Croatia: The importance of a two-step testing approach. Eur. J. Clin. Microbiol. Infect. Dis., 40.","DOI":"10.1007\/s10096-020-04019-y"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/jmv.25727","article-title":"Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis","volume":"92","author":"Zhengtu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_11","unstructured":"(2021, January 19). Covid-19, The Results of the Seroprevalence Survey Illustrated. Available online: http:\/\/www.salute.gov.it\/portale\/news\/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S994","DOI":"10.1016\/j.annonc.2020.08.1741","article-title":"1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy","volume":"31","author":"Zambelli","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e000889","DOI":"10.1136\/esmoopen-2020-000889","article-title":"SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic","volume":"5","author":"Fuereder","year":"2020","journal-title":"ESMO Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1200\/GO.20.00209","article-title":"Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic","volume":"6","author":"Ballatore","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.esmoop.2021.100053","article-title":"Social distress among Medical Oncologists and other Health Care Professionals during the first wave of COVID-19 pandemic in Italy","volume":"6","author":"Berardi","year":"2021","journal-title":"ESMO Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Barlesi, F., Foulon, S., Bayle, A., Gachot, B., Pommeret, F., Willekens, C., Stoclin, A., Merad, M., GriscelliI, F., and Micol, J.-B. (2020, January 27\u201328). Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. Proceedings of the AACR Annual Meeting 2020, Philadelphia, PA, USA.","DOI":"10.1158\/1538-7445.AM2020-CT403"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaoncol.2020.6778","article-title":"Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy","volume":"7","author":"Aschele","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bertuzzi, A.F., Marrari, A., Gennaro, N., Cariboni, U., Ciccarelli, M., Giordano, L., Quagliuolo, V.L., and Santoro, A. (2020). Low incidence of sars-cov-2 in patients with solid tumours on active treatment: An observational study at a tertiary cancer centre in lombardy, Italy. Cancers, 12.","DOI":"10.3390\/cancers12092352"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102102","DOI":"10.1016\/j.ctrv.2020.102102","article-title":"Seroprevalence of SARS-CoV-2\u2013specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data","volume":"90","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Altman, D.G. (1991). Statistics in Medicine. Practical Statistics for Medical Research, Taylor & Francis Ltd.","DOI":"10.1201\/9780429258589"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/ijc.33148","article-title":"Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19","volume":"147","author":"Liu","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.annonc.2020.10.473","article-title":"Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2","volume":"32","author":"Marra","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_24","unstructured":"(2021, January 19). World Health Organization Evidence to Recommendations for COVID-19 Vaccines: Evidence Framework. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/337569."},{"key":"ref_25","unstructured":"(2021, January 19). World Health Organization WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/334299."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/7\/1503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:26:16Z","timestamp":1760361976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/7\/1503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,4]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["jcm10071503"],"URL":"https:\/\/doi.org\/10.3390\/jcm10071503","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,4,4]]}}}